|
1
|
Lessene G, Czabotar PE and Colman PM:
Bcl-2 family antagonists for cancer therapy. Nat Rev Drug Discov.
7:989–1000. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Letai AG: Diagnosing and exploiting
cancer's addiction to blocks in apoptosis. Nat Rev Cancer.
8:121–132. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marzo I and Naval J: Bcl-2 family members
as molecular targets in cancer therapy. Biochem Pharmacol.
76:939–946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scarfò L and Ghia P: Reprogramming cell
death: Bcl2 family inhibition in hematological malignancies.
Immunol Lett. 155:36–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson MA, Deng J, Seymour JF, Tam CK,
Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, et al: The bcl2
selective inhibitor venetoclax induces rapid onset apoptosis of cll
cells in patients via a tp53-independent mechanism. Blood.
127:3215–3224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Robak T, Smolewski P, Robak P and Dreyling
M: Mantle cell lymphoma: Therapeutic options in
transplant-ineligible patients. Leuk Lymphoma. 60:2622–2634. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhatt P, Kloock C and Comenzo R:
Relapsed/refractory multiple myeloma: A review of available
therapies and clinical scenarios encountered in myeloma relapse.
Curr Oncol. 30:2322–2347. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Cheikh J, Bidaoui G, Saleh M, Moukalled
N, Dalle IA and Bazarbachi A: Venetoclax: A new partner in the
novel treatment era for acute myeloid leukemia and myelodysplastic
syndrome. Clin Hematol Int. 5:143–154. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laurenti L, Scarfò L, Frustaci AM, Sanna
A, Iannella E, Caira M, Finsinger P, Schifano S, Neri B, Molica S
and Mauro FR: Real-world evidence on venetoclax in chronic
lymphocytic leukemia: The Italian experience. Hematol Oncol.
41:621–630. 2023. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cramer P, von Tresckow J, Bahlo J,
Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer
K, Tausch E, et al: Bendamustine followed by obinutuzumab and
venetoclax in chronic lymphocytic leukaemia (cll2-bag): Primary
endpoint analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol. 19:1215–1228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seymour JF, Kipps TJ, Eichhorst B, Hillmen
P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la
Serna J, et al: Venetoclax-rituximab in relapsed or refractory
chronic lymphocytic leukemia. N Engl J Med. 378:1107–1120. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al-Sawaf O, Zhang C, Tandon M, Sinha A,
Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J,
Opat S, et al: Venetoclax plus obinutuzumab versus chlorambucil
plus obinutuzumab for previously untreated chronic lymphocytic
leukaemia (cll14): Follow-up results from a multicentre,
open-label, randomised, phase 3 trial. Lancet Oncol. 21:1188–1200.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DiNardo CD, Jonas BA, Pullarkat V, Thirman
MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, et
al: Azacitidine and venetoclax in previously untreated acute
myeloid leukemia. N Engl J Med. 383:617–629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar SK, Harrison SJ, Cavo M, de la Rubia
J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I,
et al: Venetoclax or placebo in combination with bortezomib and
dexamethasone in patients with relapsed or refractory multiple
myeloma (bellini): A randomised, double-blind, multicentre, phase 3
trial. Lancet Oncol. 21:1630–1642. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei AH, Montesinos P, Ivanov V, DiNardo
CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, et
al: Venetoclax plus ldac for newly diagnosed aml ineligible for
intensive chemotherapy: A phase 3 randomized place-bo-controlled
trial. Blood. 135:2137–2145. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
DiNardo CD, Lachowiez CA, Takahashi K,
Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K,
et al: Venetoclax combined with flag-ida induction and
consolidation in newly diagnosed and relapsed or refractory acute
myeloid leukemia. J Clin Oncol. 39:2768–2778. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei AH, Panayiotidis P, Montesinos P,
Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni
M, et al: 6-month follow-up of viale-c demonstrates improved and
durable efficacy in patients with untreated aml ineligible for
intensive chemotherapy (141/150). Blood Cancer J. 11:1632021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wierda WG, Allan JN, Siddiqi T, Kipps TJ,
Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, et al:
Ibrutinib plus venetoclax for first-line treatment of chronic
lymphocytic leukemia: Primary analysis results from the minimal
residual disease cohort of the randomized phase ii captivate study.
J Clin Oncol. 39:3853–3865. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamamoto K, Shinagawa A, DiNardo CD, Pratz
KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C,
Fukuhara N, et al: Venetoclax plus azacitidine in Japanese patients
with untreated acute myeloid leukemia ineligible for intensive
chemotherapy. Jpn J Clin Oncol. 52:29–38. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eichhorst B, Niemann CU, Kater AP,
Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M,
Juliusson G, Thornton P, et al: First-line venetoclax combinations
in chronic lymphocytic leukemia. N Engl J Med. 388:1739–1754. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Azanza JR, Mensa J, Barberán J, Vázquez L,
de Oteyza JP, Kwon M, Yáñez L, Aguado JM, Gracian AC, Solano C, et
al: Recommendations on the use of azole antifungals in
hematology-oncology patients. Rev Esp Quimioter. 3:236–258. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
U.S. Food and Drug Administration (FDA), .
Drug development and drug interactions: Table of substrates,
inhibitors and inducers. FDA, Silver Spring, MD. 2024.https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table2-2November
7–2024
|
|
23
|
Brüggemann RJ, Alffenaar JW, Blijlevens
NM, Billaud EM, Kosterink JG, Verweij PE and Burger DM: Clinical
relevance of the pharmacokinetic interactions of azole antifungal
drugs with other coadministered agents. Clin Infect Dis.
48:1441–1458. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
U.S. Food and Drug Administration (FDA), .
Venetoclax prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdfNovember
7–2024
|
|
25
|
Agarwal SK, DiNardo CD, Potluri J, Dunbar
M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY
and Salem AH: Management of venetoclax-posaconazole interaction in
acute myeloid leukemia patients: Evaluation of dose adjustments.
Clin Ther. 39:359–367. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De la Garza-Salazar F, Colunga-Pedraza PR,
Gómez-Almaguer D, García-Zárate VA and Gómez-De León A: Low dose
venetoclax plus itraconazole outpatient induction in newly
diagnosed acute myeloid leukemia: A phase 2 study. Leuk Res.
133:1073732023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute leukaemias. French-American-British
(FAB) co-operative group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grimwade D, Hills RK, Moorman AV, Walker
H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ and Burnett
AK; National Cancer Research Institute Adult Leukaemia Working
Group, : Refinement of cytogenetic classification in acute myeloid
leukemia: Determination of prognostic significance of rare
recurring chromosomal abnormalities among 5876 younger adult
patients treated in the UK MRC trials. Blood. 116:354–365. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
National Cancer Institute, . Terminology
Criteria for Adverse Events (CTCAE). Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5×7.pdfNovember
7–2024
|
|
31
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of aml in adults: 2017 eln
recommendations from an international expert panel. Blood.
129:424–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Estey E and Döhner H: Acute myeloid
leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Klepin HD, Geiger AM, Tooze JA,
Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR and Powell BL:
Geriatric assessment predicts survival for older adults receiving
induction chemotherapy for acute myelogenous leukemia. Blood.
121:4287–4294. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
National comprehensive cancer network
(NCCN), . Clinical Practice Guidelines in Oncology (NCCN
Guidelines®): Acute myeloid leukemia, Version (3.2024).
NCCN, Plymouth Meeting, PA. 2024.https://www.nccn.org/professionals/physician_gls/pdf/aml.pdfNovember
7–2024
|
|
35
|
Aldoss I, Dadwal S, Zhang J, Tegtmeier B,
Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, et al:
Invasive fungal infections in acute myeloid leukemia treated with
venetoclax and hypomethylating agents. Blood Adv. 10:4043–4049.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang A, Johnson T, Abbott D, Phupitakphol
T, Gutman JA, Pollyea DA and Koullias Y: Incidence of invasive
fungal infections in patients with previously untreated acute
myeloid leukemia receiving venetoclax and azacitidine. Open Forum
Infect Dis. 9:ofac4862022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
AlAsmari AF, Alghamdi A, Ali N, Almeaikl
MA, Hakami HM, Alyousef MK, AlSwayyed M, Alharbi M, Alqahtani F,
Alasmari F and Alsaleh N: Venetoclax induces cardiotoxicity through
modulation of oxidative-stress-mediated cardiac inflammation and
apoptosis via NF-κB and BCL-2 pathway. Int J Mol Sci. 23:62602022.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Freise KJ, Hu B and Salem AH: Impact of
ritonavir dose and schedule on cyp3a inhibition and venetoclax
clinical pharmacokinetics. Eur J Clin Pharmacol. 74:413–421. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Agarwal SK, Salem AH, Danilov AV, Hu B,
Puvvada S, Gutierrez M, Chien D, Lewis LD and Wong SL: Effect of
ketoconazole, a strong cyp3a inhibitor, on the pharmacokinetics of
venetoclax, a BCL-2 inhibitor, in patients with non-hodgkin
lymphoma. Br J Clin Pharmacol. 83:846–854. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De la Garza-Salazar F, Peña-Lozano SP and
Gómez-Almaguer D and Gómez-Almaguer D: Orbital myeloid sarcoma
treated with low-dose venetoclax and a potent cytochrome p450
inhibitor. J Oncol Pharm Pract. 29:493–497. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
De la Garza-Salazar F, Colunga-Pedraza PR
and Gómez-Almaguer D: Cytochrome p450 inhibition to decrease dosage
and costs of venetoclax and ibrutinib: A proof-of-concept case
study. Br J Clin Pharmacol. 89:898–902. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bhatnagar S, Mukherjee D and Salem AH:
Dose adjustment of venetoclax when co-administered with
posaconazole: Clinical drug-drug interaction predictions using a
pbpk approach. Cancer Chemother Pharmacol. 87:465–474. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kobayashi M, Yasu T, Suzaki K and Kosugi
N: Utility of therapeutic drug monitoring of venetoclax in acute
myeloid leukemia. Oncology. 39:1–5. 2022.
|
